Cabaletta Bio 已成功获得监管机构对其新药申请（IND）修正案的许可，该修正案涉及使用 Cellares 公司的自动化平台进行 Rese-Cel 的临床生产。这一进展标志着 Cabaletta Bio 在推进其细胞疗法候选药物 Rese-Cel 的临床开发方面迈出了重要一步。通过利用 Cellares 的先进自动化技术，Cabaletta Bio 旨在提高生产效率、确保产品质量的一致性，并加速 Rese-Cel 的临床供应。此次合作结合了 Cabaletta Bio 在细胞治疗领域的专业知识和 Cellares 的创新型制造解决方案，有望为患者带来更高效、可靠的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.